Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients

By Yahoo! Finance | Oct 3, 2024 at 10:56 AM EST

Theriva Biologics reported positive results from the Phase 1b/2a trial of SYN-004 in preventing acute graft-versus-host disease in bone marrow transplant patients. The DSMC recommended proceeding to enroll Cohort 3 based on safety and pharmacokinetic data.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.